Literature DB >> 3815397

Pharmacokinetic comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers.

M L Citron, J R Reynolds, J Kalra, B G Kay, K A Nathan, N D Jaffe, F R Miller.   

Abstract

This was a randomized, crossover study of the bioavailability and pharmacokinetics of metoclopramide given by intranasal (IN), oral (PO), and intramuscular (IM) routes. The formulations tested were 5 and 10 mg of IN gel, 10 mg PO, and 5 mg IM. The findings showed that metoclopramide follows similar absorption and elimination characteristics when given via these three extravascular routes. There were no statistically significant differences in the area under the drug concentration versus time curve (AUC) or peak metoclopramide plasma concentration (Cmax) data following PO, IM, or 10-mg IN administration. However, the 5-mg IN doses achieved an AUC that was 39.5% the AUC of the 10-mg IN dose. These data show consistent and relatively predictable metoclopramide plasma concentrations following IN administration. Further, 10-mg doses of IN and PO metoclopramide appear to be bioequivalent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815397

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Metoclopramide role in preventing ileus after cesarean, a clinical trial.

Authors:  Jila Agah; Roya Baghani; Mohammad Hassan Rakhshani; Abolfazl Rad
Journal:  Eur J Clin Pharmacol       Date:  2015-04-15       Impact factor: 2.953

2.  Bioavailability of intranasal metoclopramide.

Authors:  M J Ward; D C Buss; J Ellershaw; A Nash; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

Review 3.  Anti-emetics for cancer chemotherapy-induced emesis: Potential of alternative delivery systems.

Authors:  L Kraut; A A Fauser
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Intranasal metoclopramide.

Authors:  D Ormrod; K L Goa
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.